Outlook Therapeutics (OTLK) Expected to Announce Quarterly Earnings on Wednesday

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect Outlook Therapeutics to post earnings of ($0.85) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Outlook Therapeutics Price Performance

NASDAQ:OTLK traded down $0.02 during midday trading on Friday, hitting $1.71. The company's stock had a trading volume of 427,967 shares, compared to its average volume of 811,556. Outlook Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $12.85. The firm has a market cap of $54.69 million, a P/E ratio of -0.19 and a beta of 0.58. The firm's 50 day moving average is $1.87 and its 200-day moving average is $4.72.

Analyst Upgrades and Downgrades

OTLK has been the topic of a number of research reports. Guggenheim reiterated a "buy" rating and issued a $12.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. Chardan Capital reissued a "neutral" rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, BTIG Research dropped their target price on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Outlook Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $27.40.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.